Vor Biopharma Stock Buy Hold or Sell Recommendation
| VOR Stock | USD 0.82 0.03 3.80% |
Considering the 90-day investment horizon and your above-average risk tolerance, our recommendation regarding Vor Biopharma is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Vor Biopharma given historical horizon and risk tolerance towards Vor Biopharma. When Macroaxis issues a 'buy' or 'sell' recommendation for Vor Biopharma, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Vor Biopharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Vor Stock, please use our How to Invest in Vor Biopharma guide. Note, we conduct extensive research on individual companies such as Vor and provide practical buy, sell, or hold advice based on investors' constraints. Vor Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.
Vor |
Execute Vor Biopharma Buy or Sell Advice
The Vor recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Vor Biopharma. Macroaxis does not own or have any residual interests in Vor Biopharma or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Vor Biopharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Unstable | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Vor Biopharma Trading Alerts and Improvement Suggestions
| Vor Biopharma had very high historical volatility over the last 90 days | |
| Vor Biopharma has some characteristics of a very speculative penny stock | |
| Vor Biopharma has a very high chance of going through financial distress in the upcoming years | |
| Reported Net Loss for the year was (117.86 M) with profit before taxes, overhead, and interest of 0. | |
| Vor Biopharma has about 151.09 M in cash with (100.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.97, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Vor Biopharma has a frail financial position based on the latest SEC disclosures | |
| Over 81.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from news.google.com: Vor Biopharma Inc. Receives 11.36 Average PT from Analysts - MarketBeat |
Vor Biopharma current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Vor analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Vor analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Strong Buy
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Vor Biopharma Returns Distribution Density
The distribution of Vor Biopharma's historical returns is an attempt to chart the uncertainty of Vor Biopharma's future price movements. The chart of the probability distribution of Vor Biopharma daily returns describes the distribution of returns around its average expected value. We use Vor Biopharma price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Vor Biopharma returns is essential to provide solid investment advice for Vor Biopharma.
| Mean Return | -0.1 | Value At Risk | -7.78 | Potential Upside | 9.64 | Standard Deviation | 5.23 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Vor Biopharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Vor Stock Institutional Investors
The Vor Biopharma's institutional investors refer to entities that pool money to purchase Vor Biopharma's securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | Millennium Management Llc | 2024-06-30 | 389.6 K | Goldman Sachs Group Inc | 2024-06-30 | 375.3 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 338.6 K | Ensign Peak Advisors Inc | 2024-09-30 | 329.4 K | Susquehanna International Group, Llp | 2024-06-30 | 247.2 K | Jane Street Group Llc | 2024-06-30 | 222.5 K | Two Sigma Investments Llc | 2024-09-30 | 137.1 K | Bridgeway Capital Management, Llc | 2024-09-30 | 135.9 K | Exchange Traded Concepts, Llc | 2024-06-30 | 117.8 K | Ra Capital Management, Llc | 2024-09-30 | 22.7 M | Fmr Inc | 2024-09-30 | 7.1 M |
Vor Biopharma Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 7.1M | 42.1M | 72.1M | (62.1M) | (26.3M) | (25.0M) | |
| Free Cash Flow | (10.6M) | (40.5M) | (73.0M) | (93.6M) | (101.4M) | (96.3M) | |
| Depreciation | 91K | 605K | 1.4M | 2.5M | 3.5M | 3.7M | |
| Other Non Cash Items | 608K | 782K | 3.2M | 6.4M | 67K | 63.7K | |
| Net Income | (10.8M) | (43.3M) | (68.9M) | (92.1M) | (117.9M) | (112.0M) | |
| End Period Cash Flow | 8.0M | 50.1M | 122.2M | 60.1M | 33.8M | 50.4M | |
| Change To Netincome | 748K | 2.1M | 4.5M | 10.7M | 12.3M | 12.9M |
Vor Biopharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Vor Biopharma or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Vor Biopharma's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Vor stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.38 | |
β | Beta against Dow Jones | 2.25 | |
σ | Overall volatility | 5.23 | |
Ir | Information ratio | -0.04 |
Vor Biopharma Volatility Alert
Vor Biopharma exhibits very low volatility with skewness of 1.29 and kurtosis of 3.11. Vor Biopharma is a potential penny stock. Although Vor Biopharma may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Vor Biopharma. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Vor instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Vor Biopharma Fundamentals Vs Peers
Comparing Vor Biopharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Vor Biopharma's direct or indirect competition across all of the common fundamentals between Vor Biopharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Vor Biopharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Vor Biopharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Vor Biopharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Vor Biopharma to competition |
| Fundamentals | Vor Biopharma | Peer Average |
| Return On Equity | -0.78 | -0.31 |
| Return On Asset | -0.4 | -0.14 |
| Current Valuation | 24.3 M | 16.62 B |
| Shares Outstanding | 68.67 M | 571.82 M |
| Shares Owned By Insiders | 1.17 % | 10.09 % |
| Shares Owned By Institutions | 81.20 % | 39.21 % |
| Number Of Shares Shorted | 1.37 M | 4.71 M |
| Price To Book | 0.74 X | 9.51 X |
| EBITDA | (114.37 M) | 3.9 B |
| Net Income | (117.86 M) | 570.98 M |
| Cash And Equivalents | 151.09 M | 2.7 B |
| Cash Per Share | 3.97 X | 5.01 X |
| Total Debt | 35.66 M | 5.32 B |
| Debt To Equity | 0.24 % | 48.70 % |
| Current Ratio | 12.95 X | 2.16 X |
| Book Value Per Share | 2.22 X | 1.93 K |
| Cash Flow From Operations | (100.29 M) | 971.22 M |
| Short Ratio | 2.99 X | 4.00 X |
| Earnings Per Share | (1.64) X | 3.12 X |
| Target Price | 11.92 | |
| Number Of Employees | 168 | 18.84 K |
| Beta | -0.41 | -0.15 |
| Market Capitalization | 54.25 M | 19.03 B |
| Total Asset | 198.13 M | 29.47 B |
| Retained Earnings | (340.08 M) | 9.33 B |
| Working Capital | 125.23 M | 1.48 B |
| Net Asset | 198.13 M |
Note: Disposition of 2788 shares by Ang Robert of Vor Biopharma at 2.32 subject to Rule 16b-3 [view details]
Vor Biopharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Vor . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Vor Biopharma Buy or Sell Advice
When is the right time to buy or sell Vor Biopharma? Buying financial instruments such as Vor Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Vor Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Tech Funds Thematic Idea Now
Tech Funds
Funds or Etfs that invest in companies involved in research, development, testing, or distribution of technologically based goods and services. The Tech Funds theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Tech Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Vor Stock Analysis
When running Vor Biopharma's price analysis, check to measure Vor Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vor Biopharma is operating at the current time. Most of Vor Biopharma's value examination focuses on studying past and present price action to predict the probability of Vor Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vor Biopharma's price. Additionally, you may evaluate how the addition of Vor Biopharma to your portfolios can decrease your overall portfolio volatility.